ADP-dependent glucokinase (ADPGK) is not critical for the activation of human macrophages by LPS-Immunometabolism-CSCIED科技核心评价数据库-手机版

ADP-dependent glucokinase (ADPGK) is not critical for the activation of human macrophages by LPS

ADP-dependent glucokinase (ADPGK) is not critical for the activation of human macrophages by LPS

ES评分 0 浏览量：614 下载量：0

DOI	10.1097/IN9.0000000000000006
刊名	Immunometabolism IJ
年，卷(期)	2022, 4(3)
作者	Geiger, Benjamin; Wang, Bei-Tzu; Munteanu, Bogdan; Riedel, Jens; Zezina, Ekaterina; Biesemann, Nadine; Schmoll, Dieter,
作者单位	[Geiger, Benjamin; Zezina, Ekaterina; Biesemann, Nadine; Schmoll, Dieter] Sanofi R&D, TA Immunol, Ind pk Hoechst, Frankfurt, Germany; [Wang, Bei-Tzu; Munteanu, Bogdan; Riedel, Jens] Sanofi R&D, Drug Metab & Pharmacokinet, Metab Imaging Mass Spectrometry G
摘要	Background:Activated immune cells show an enhanced glucose metabolism, suggesting that the inhibition of this pathway selective in immune cells could be a potential approach to combat inflammatory diseases. We studied here whether ADP-dependent glucokinase (ADPGK), a glucose-phosphorylating enzyme predominantly expressed in immune cells, could be a suitable target for the inhibition of macrophage activation.Methods:The regulation and role of ADPGK in human primary macrophages differentiated from blood monocytes was studied using Real-time quantitative PCR (RT-qPCR), gene silencing, whole-cell MALDI-mass spectrometry (MS) imaging as well as immune-based and enzymatic medium analyzes.Results:The expression of ADPGK was induced in response to the activation of toll-like receptors (TLRs). The most robust effect was observed with the TLR4 ligand Lipopolysaccharide (LPS) leading to an approximately 4-fold increase of ADPGK RNA levels. For this induction, the activation of p38 MAPK and IKK epsilon was important. Silencing of ADPGK expression using siRNAs had neither an effect on LPS-induced expression and release of proinflammatory cytokines nor on cellular ATP levels and lactate production. Untargeted metabolic cell profiling by whole-cell MALDI-MS imaging did not reveal any metabolic regulations after ADPGK down-regulation suggesting no specific metabolic pathway involvement.Conclusions:ADPGK neither catalyzes a rate-limiting step of glucose metabolism in LPS-activated macrophages nor is required for the proinflammatory phenotype of these cells in vitro. Our data do not indicate that ADPGK inhibition could be a pharmacological approach to modulate immunometabolism.
Abstract	Background:Activated immune cells show an enhanced glucose metabolism, suggesting that the inhibition of this pathway selective in immune cells could be a potential approach to combat inflammatory diseases. We studied here whether ADP-dependent glucokinase (ADPGK), a glucose-phosphorylating enzyme predominantly expressed in immune cells, could be a suitable target for the inhibition of macrophage activation.Methods:The regulation and role of ADPGK in human primary macrophages differentiated from blood monocytes was studied using Real-time quantitative PCR (RT-qPCR), gene silencing, whole-cell MALDI-mass spectrometry (MS) imaging as well as immune-based and enzymatic medium analyzes.Results:The expression of ADPGK was induced in response to the activation of toll-like receptors (TLRs). The most robust effect was observed with the TLR4 ligand Lipopolysaccharide (LPS) leading to an approximately 4-fold increase of ADPGK RNA levels. For this induction, the activation of p38 MAPK and IKK epsilon was important. Silencing of ADPGK expression using siRNAs had neither an effect on LPS-induced expression and release of proinflammatory cytokines nor on cellular ATP levels and lactate production. Untargeted metabolic cell profiling by whole-cell MALDI-MS imaging did not reveal any metabolic regulations after ADPGK down-regulation suggesting no specific metabolic pathway involvement.Conclusions:ADPGK neither catalyzes a rate-limiting step of glucose metabolism in LPS-activated macrophages nor is required for the proinflammatory phenotype of these cells in vitro. Our data do not indicate that ADPGK inhibition could be a pharmacological approach to modulate immunometabolism.
关键词	inflammation; immunity; glucose; macrophages; hexokinase; energy metabolism
KeyWord	inflammation; immunity; glucose; macrophages; hexokinase; energy metabolism
基金项目
页码	1-10

参考文献
相关文献

[1]. Pålsson-McDermott EM, OʼNeill LAJ. Targeting immunometabolism as an anti-inflammatory strategy. Cell Res. 2020;30:300–14.

[2]. OʼNeill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553–65.

[3]. Piranavan P, Bhamra M, Perl A. Metabolic targets for treatment of autoimmune diseases. Immunometabolism. 2020;2:e200012.

[4]. Thorp EB. Macrophage metabolic signaling during ischemic injury and cardiac repair. Immunometabolism. 2021;3:e210018.

[5]. Mangal JL, Basu N, Wu H-JJ, et al. Immunometabolism: an emerging target for immunotherapies to treat rheumatoid arthritis. Immunometabolism. 2021;3:e210032.

[6]. Godfrey WH, Kornberg MD. The role of metabolic enzymes in the regulation of inflammation. Metabolites. 2020;10:426426.

[7]. Soto-Heredero G, Gómez de Las Heras MM, Gabandé-Rodríguez E, et al. Glycolysis—a key player in the inflammatory response. FEBS J. 2020;287:3350–69.

[8]. Zezina E, Sercan-Alp O, Herrmann M, et al. Glucose transporter 1 in rheumatoid arthritis and autoimmunity. Wiley Interdiscip Rev Syst Biol Med. 2020;12:e1483.

[9]. Kornberg MD. The immunologic Warburg effect: evidence and therapeutic opportunities in autoimmunity. Wiley Interdiscip Rev Syst Biol Med. 2020;12:e1486.

[10]. Wilson JE. Hexokinases. Rev Physiol Biochem Pharmacol. 1995;126:65–198.

[11]. Ronimus RS, Morgan HW. Cloning and biochemical characterization of a novel mouse ADP-dependent glucokinase. Biochem Biophys Res Commun. 2004;315:652–8.

[12]. Richter S, Richter JP, Mehta SY, et al. Expression and role in glycolysis of human ADP-dependent glucokinase. Mol Cell Biochem. 2012;364:131–45.

[13]. Kamiński MM, Sauer SW, Kamińński M, et al. T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation. Cell Rep. 2012;2:1300–15.

[14]. Imle R, Wang BT, Stützenberger N, et al. ADP-dependent glucokinase regulates energy metabolism via ER-localized glucose sensing. Sci Rep. 2019;9:14248.

[15]. Tandon A, Birkenhagen J, Nagalla D, et al. ADP-dependent glucokinase as a novel onco-target for haematological malignancies. Sci Rep. 2020;10:13584.

[16]. Lee JH, Zhao XM, Yoon I, et al. Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discov. 2016;2:16025.

[17]. Jing Y, Liu J, Ye Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11:4946.

[18]. Richter S, Morrison S, Connor T, et al. Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism. PLoS One. 2013;8:e65267.

[19]. Richter JP, Goroncy AK, Ronimus RS, et al. The structural and functional characterization of mammalian ADP-dependent glucokinase. J Biol Chem. 2016;291:3694–704.

[20]. Jiménez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors--from microbial recognition to autoimmunity: a comprehensive review. Autoimmun Rev. 2016;15:1–8.

[21]. Wu R, Chen F, Wang N, et al. ACOD1 in immunometabolism and disease. Cell Mol Immunol. 2020;17:822–33.

[22]. Ryan DG, OʼNeill LAJ. Krebs cycle reborn in macrophage immunometabolism. Annu Rev Immunol. 2020;38:289–313.

[23]. Hooftman A, OʼNeill LAJ. The immunomodulatory potential of the metabolite itaconate. Trends Immunol. 2019;40:687–98.

[24]. He W, Heinz A, Jahn D, et al. Complexity of macrophage metabolism in infection. Curr Opin Biotechnol. 2021;68:231–9.

[25]. Zhu L, Zhao Q, Yang T, et al. Cellular metabolism and macrophage functional polarization. Int Rev Immunol. 2015;34:82–100.

[26]. Clark K, Peggie M, Plater L, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011;434:93–104.

[27]. Ziegler N, Bader E, Epanchintsev A, et al. AMPKβ1 and AMPKβ2 define an isoform-specific gene signature in human pluripotent stem cells, differentially mediating cardiac lineage specification. J Biol Chem. 2020;295:17659–71.

[28]. Hinsenkamp I, Schulz S, Roscher M, et al. Inhibition of Rho-associated kinase 1/2 attenuates tumor growth in murine gastric cancer. Neoplasia. 2016;18:500–11.

[29]. Schramm T, Hester Z, Klinkert I, et al. imzML—a common data format for the flexible exchange and processing of mass spectrometry imaging data. J Proteomics. 2012;75:5106–10.

[30]. Inglese P, Correia G, Takats Z, et al. SPUTNIK: an R package for filtering of spatially related peaks in mass spectrometry imaging data. Bioinformatics. 2019;35:178–80.

[31]. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297–315.

[32]. Totzke J, Gurbani D, Raphemot R, et al. Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-α inhibition for cancer and autoimmune disease. Cell Chem Biol. 2017;24:1029–39.e7.

[33]. Gay NJ, Symmons MF, Gangloff M, et al. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. 2014;14:546–58.

[34]. Perrin-Cocon L, Aublin-Gex A, Diaz O, et al. Toll-like receptor 4-induced glycolytic burst in human monocyte-derived dendritic cells results from p38-dependent stabilization of HIF-1α and increased hexokinase II expression. J Immunol. 2018;201:1510–21.

[35]. Munteanu B, von Reitzenstein C, Hänsch GM, et al. Sensitive, robust and automated protein analysis of cell differentiation and of primary human blood cells by intact cell MALDI mass spectrometry biotyping. Anal Bioanal Chem. 2012;404:2277–86.

[36]. Karikó K, Bhuyan P, Capodici J, et al. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol. 2004;172:6545–9.

[37]. Veiga-da-Cunha M, Chevalier N, Stephenne X, et al. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proc Natl Acad Sci USA. 2019;116:1241–50.

[38]. Zhang K, Wang Q, Liang Y, et al. Quantitative proteomic analysis of mouse sciatic nerve reveals post-injury upregulation of ADP-dependent glucokinase promoting macrophage phagocytosis. Front Mol Neurosci. 2021;14:777621.

引用本文

Geiger, Benjamin; Wang, Bei-Tzu; Munteanu, Bogdan; Riedel, Jens; Zezina, Ekaterina; Biesemann, Nadine; Schmoll, Dieter. ADP-dependent glucokinase (ADPGK) is not critical for the activation of human macrophages by LPS [J]. Immunometabolism. 2022; 4; (3). 1 - 10.

文献评论

相关学者

相关机构